This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 570

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

By Adam Feuerstein

On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.

01:04PM 09/16/14

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

By Adam Feuerstein

Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.

09:48AM 09/16/14

Avanir's Over-Priced Cough Syrup Touted for Role in Alzheimer's Agitation

By Adam Feuerstein

Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high

10:19AM 09/15/14

NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel

By Adam Feuerstein

NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.

09:32AM 09/15/14

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

By Adam Feuerstein

Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.

09:43AM 09/12/14

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

By Adam Feuerstein

Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.

02:20PM 09/11/14

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

By Adam Feuerstein

Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

01:23PM 09/11/14

Medivation Prostate Cancer Drug Secures Expanded FDA Label

By Adam Feuerstein

Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.

03:37PM 09/10/14

J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig

By Adam Feuerstein

Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.

08:48AM 09/08/14

Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label

By Adam Feuerstein

Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.

07:00AM 09/08/14

« Back
Page 1 of 570

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs